AR115455A1 - Derivado de piridotriazina policíclica - Google Patents
Derivado de piridotriazina policíclicaInfo
- Publication number
- AR115455A1 AR115455A1 ARP190101467A ARP190101467A AR115455A1 AR 115455 A1 AR115455 A1 AR 115455A1 AR P190101467 A ARP190101467 A AR P190101467A AR P190101467 A ARP190101467 A AR P190101467A AR 115455 A1 AR115455 A1 AR 115455A1
- Authority
- AR
- Argentina
- Prior art keywords
- taken together
- alkyl
- membered non
- ring
- independently
- Prior art date
Links
- HHQDNOXLJMIISM-UHFFFAOYSA-N pyrido[3,2-d]triazine Chemical class C1=NN=NC2=CC=CN=C21 HHQDNOXLJMIISM-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical class 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado por la formula (1) o su sal aceptable desde el punto de vista farmacéutico, en donde el anillo A de fórmula (2) es el anillo de fórmula (3) ó (4); X¹ es CR⁹ᵃR⁹ᵇ u O; R⁵ᵃ, R⁵ᵇ, R⁶ᵃ, R⁶ᵇ, R⁷ᵃ y R⁷ᵇ son, cada uno independientemente, un átomo de hidrógeno, alquilo, alquiloxi o alquiloxialquilo; R⁵ᵃ y R⁶ᵃ, o R⁶ᵃ y R⁷ᵃ se pueden tomar junto con los átomos adyacentes para formar un carbociclo aromático opcionalmente sustituido con halógeno, un carbociclo no aromático de 3 a 6 miembros opcionalmente sustituido con halógeno o un heterociclo no aromático de 4 a 6 miembros opcionalmente sustituido con halógeno (siempre que en caso de formar un carbociclo aromático, R⁵ᵇ y R⁶ᵇ, o R⁶ᵇ y R⁷ᵇ se puedan tomar juntos para formar un enlace); R⁵ᵇ y R⁶ᵇ se pueden tomar juntos para formar un enlace; R⁸ᵃ, R⁸ᵇ, R⁹ᵃ, R⁹ᵇ, R¹⁰ᵃ, R¹⁰ᵇ, R¹¹ᵃ y R¹¹ᵇ son, cada uno independientemente, un átomo de hidrógeno, alquilo, alquiloxi o alquiloxialquilo; R⁸ᵃ y R¹⁰ᵃ se pueden tomar juntos para formar un puente C₁₋₃; R¹⁰ᵃ y R¹¹ᵃ se pueden tomar en conjunto con los átomos adyacentes para formar un carbociclo no aromático de 5 miembros; R⁹ᵃ y R⁹ᵇ se pueden tomar junto con el átomo adyacente para formar un carbociclo no aromático de 4 miembros o un heterociclo no aromático de 5 miembros; R⁸ᵃ y R⁹ᵃ se pueden tomar juntos para formar un enlace; el anillo B es un anillo de benceno o un anillo de piridina; Q es -NHC(O)- o un heterociclo aromático de 5 miembros; R¹ es, cada uno independientemente, halógeno, alquilo, haloalquilo, alquiloxi, ciano o haloalquiloxi, R²ᵃ y R²ᵇ son, cada uno independientemente, un átomo de hidrógeno, alquilo o haloalquilo; R³ es alquilo o haloalquilo; R⁴ es un átomo de hidrógeno o alquilo; y n es un entero de 1 a 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018104156 | 2018-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115455A1 true AR115455A1 (es) | 2021-01-20 |
Family
ID=68698918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101467A AR115455A1 (es) | 2018-05-31 | 2019-05-30 | Derivado de piridotriazina policíclica |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11649236B2 (es) |
| EP (2) | EP4257137A3 (es) |
| JP (2) | JP7328962B2 (es) |
| KR (1) | KR20210015922A (es) |
| CN (2) | CN117327072A (es) |
| AR (1) | AR115455A1 (es) |
| AU (2) | AU2019277548B2 (es) |
| BR (1) | BR112020024077A2 (es) |
| CA (1) | CA3102063A1 (es) |
| CL (1) | CL2020003002A1 (es) |
| CO (1) | CO2020014294A2 (es) |
| CR (2) | CR20230571A (es) |
| DK (1) | DK3805220T3 (es) |
| DO (1) | DOP2020000221A (es) |
| EA (1) | EA202092921A1 (es) |
| FI (1) | FI3805220T3 (es) |
| IL (2) | IL313474A (es) |
| LT (1) | LT3805220T (es) |
| MA (1) | MA52795A (es) |
| MX (2) | MX2020012176A (es) |
| PE (1) | PE20210477A1 (es) |
| PH (1) | PH12020552000A1 (es) |
| SG (1) | SG11202011382PA (es) |
| WO (1) | WO2019230858A1 (es) |
| ZA (1) | ZA202007567B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3938047T (pt) | 2019-03-22 | 2022-10-03 | Gilead Sciences Inc | Compostos de carbamoilpiridona tricíclicos em ponte e seus uso farmacêutico |
| EP4066839A4 (en) * | 2019-11-28 | 2023-12-27 | Shionogi & Co., Ltd | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED IN THAT IT COMPRISES A COMBINATION OF AN INTEGRASE INHIBITOR AND AN ANTI-HIV AGENT |
| JPWO2021107065A1 (es) * | 2019-11-28 | 2021-06-03 | ||
| MX2022009871A (es) | 2020-02-24 | 2022-08-19 | Gilead Sciences Inc | Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih). |
| WO2021233302A1 (zh) * | 2020-05-21 | 2021-11-25 | 南京明德新药研发有限公司 | 稠环衍生物及其在药学上的应用 |
| MX2023001194A (es) * | 2020-07-27 | 2023-04-20 | Merck Sharp & Dohme Llc | Inhibidores de la endonucleasa policiclicos dependientes de la capside para el tratamiento o la prevencion de la influenza. |
| PE20231297A1 (es) | 2021-01-19 | 2023-08-22 | Gilead Sciences Inc | Compuestos de piridotriazina sustituidos y usos de estos |
| CN117751118A (zh) * | 2021-07-30 | 2024-03-22 | 吉斯凯(苏州)制药有限公司 | 大环吡啶酮类化合物及其应用 |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024061257A1 (zh) * | 2022-09-20 | 2024-03-28 | 吉斯凯(苏州)制药有限公司 | 多环氮杂环酮类化合物及其应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006506352A (ja) | 2002-09-11 | 2006-02-23 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物 |
| WO2004058756A1 (en) | 2002-12-27 | 2004-07-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| ATE516026T1 (de) | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
| PT1874117E (pt) | 2005-04-28 | 2013-10-17 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse |
| US8188271B2 (en) | 2005-10-27 | 2012-05-29 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| BR112012021595A2 (pt) | 2010-02-26 | 2017-02-21 | Japan Tobacco Inc | "composto derivado de 1,3,4,8-tetra-hidro-2h-pirido[1,2-a]pirazina, suas composições, seus usos, agente anti-hiv, inibidor da integrase de hiv e embalagem comercial" |
| US9216995B2 (en) | 2010-04-12 | 2015-12-22 | Shionogi & Co., Ltd. | Pyridone derivative having integrase inhibitory activity |
| RU2014113230A (ru) | 2011-10-12 | 2015-11-20 | Шионоги Энд Ко., Лтд. | Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы |
| EP2931730B1 (en) * | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| PL2822954T3 (pl) | 2012-12-21 | 2016-09-30 | Policykliczne związki karbamoilopirydonu i ich farmaceutyczne zastosowanie | |
| US10087178B2 (en) | 2012-12-27 | 2018-10-02 | Japan Tobacco Inc. | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor |
| RS56701B1 (sr) | 2013-05-17 | 2018-03-30 | Merck Sharp & Dohme | Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze |
| WO2014200880A1 (en) * | 2013-06-13 | 2014-12-18 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
| SI3252058T1 (sl) | 2013-07-12 | 2021-03-31 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV |
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| CA2924829C (en) | 2013-09-27 | 2019-10-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| WO2015089847A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2015199167A1 (ja) | 2014-06-25 | 2015-12-30 | 日本たばこ産業株式会社 | 置換されたスピロピリド［１，２－ａ］ピラジン誘導体の製造方法および中間体 |
| WO2016027879A1 (ja) | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
| WO2016094198A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| US10081647B2 (en) | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| NZ735575A (en) | 2015-04-02 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| EP3377065B1 (en) | 2015-11-17 | 2022-05-18 | Merck Sharp & Dohme Corp. | Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors |
| WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
| WO2017106071A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| US11413292B2 (en) | 2018-02-15 | 2022-08-16 | Merck, Sharp & Dohme LLC | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| CN112088005A (zh) | 2018-04-27 | 2020-12-15 | 默沙东公司 | 可用作hiv整合酶抑制剂的三环杂环化合物 |
| CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| IL279050B1 (en) | 2018-05-31 | 2024-08-01 | Shionogi & Co | Consequence of polycyclic pyridone |
| US11884683B2 (en) | 2018-06-05 | 2024-01-30 | Merck Sharp & Dohme Llc | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| CN108957755B (zh) | 2018-07-27 | 2021-04-30 | 京东方科技集团股份有限公司 | 一种显示组件及其控制方法、平视显示器及汽车 |
| PT3938047T (pt) | 2019-03-22 | 2022-10-03 | Gilead Sciences Inc | Compostos de carbamoilpiridona tricíclicos em ponte e seus uso farmacêutico |
-
2019
- 2019-05-30 EP EP23192706.2A patent/EP4257137A3/en active Pending
- 2019-05-30 MA MA052795A patent/MA52795A/fr unknown
- 2019-05-30 KR KR1020207037580A patent/KR20210015922A/ko not_active Application Discontinuation
- 2019-05-30 CN CN202311258763.1A patent/CN117327072A/zh active Pending
- 2019-05-30 WO PCT/JP2019/021446 patent/WO2019230858A1/ja active Application Filing
- 2019-05-30 LT LTEPPCT/JP2019/021446T patent/LT3805220T/lt unknown
- 2019-05-30 PE PE2020001863A patent/PE20210477A1/es unknown
- 2019-05-30 CR CR20230571A patent/CR20230571A/es unknown
- 2019-05-30 SG SG11202011382PA patent/SG11202011382PA/en unknown
- 2019-05-30 CA CA3102063A patent/CA3102063A1/en active Pending
- 2019-05-30 FI FIEP19810498.6T patent/FI3805220T3/fi active
- 2019-05-30 AR ARP190101467A patent/AR115455A1/es unknown
- 2019-05-30 DK DK19810498.6T patent/DK3805220T3/da active
- 2019-05-30 EP EP19810498.6A patent/EP3805220B1/en active Active
- 2019-05-30 EA EA202092921A patent/EA202092921A1/ru unknown
- 2019-05-30 IL IL313474A patent/IL313474A/en unknown
- 2019-05-30 JP JP2020522577A patent/JP7328962B2/ja active Active
- 2019-05-30 BR BR112020024077-0A patent/BR112020024077A2/pt unknown
- 2019-05-30 AU AU2019277548A patent/AU2019277548B2/en active Active
- 2019-05-30 CN CN201980050399.5A patent/CN112513042B/zh active Active
- 2019-05-30 MX MX2020012176A patent/MX2020012176A/es unknown
- 2019-05-30 CR CR20200644A patent/CR20200644A/es unknown
- 2019-05-30 US US17/058,251 patent/US11649236B2/en active Active
-
2020
- 2020-11-13 MX MX2023010377A patent/MX2023010377A/es unknown
- 2020-11-18 CO CONC2020/0014294A patent/CO2020014294A2/es unknown
- 2020-11-18 CL CL2020003002A patent/CL2020003002A1/es unknown
- 2020-11-20 PH PH12020552000A patent/PH12020552000A1/en unknown
- 2020-11-27 DO DO2020000221A patent/DOP2020000221A/es unknown
- 2020-11-29 IL IL279051A patent/IL279051A/en unknown
- 2020-12-04 ZA ZA2020/07567A patent/ZA202007567B/en unknown
-
2023
- 2023-03-22 US US18/124,827 patent/US20230227454A1/en active Pending
- 2023-08-03 JP JP2023127333A patent/JP2023145723A/ja active Pending
-
2024
- 2024-02-08 AU AU2024200783A patent/AU2024200783A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115455A1 (es) | Derivado de piridotriazina policíclica | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CO2017010384A2 (es) | Derivados de piridona policíclica sustituida y profármaco de los mismos | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR111689A1 (es) | Tienopiridinas y benzotiofenos útiles como inhibidores de irak4 | |
| AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR117978A1 (es) | Inhibidores de 15-pgdh | |
| AR102799A1 (es) | Profármacos de agonistas fenólicos de trpv1 | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR059619A1 (es) | Derivados halogenados de sulfonamidas | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| PE20240928A1 (es) | Derivados de triazina y su uso en el tratamiento del cancer | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR096423A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona |